XRAY's Q2 Earnings Beat Meets Steady Guidance and Margin Pressure

XRAY reported Q2 adjusted EPS of 52 cents, beating the 36-cent consensus by 44%, though revenue declined 4.1% year-over-year. The dental equipment maker held full-year 2026 guidance steady at $3.5–3.6 billion in sales and $1.40–1.50 adjusted EPS, signaling management confidence despite top-line headwinds.

Wellspect Healthcare, the company's continence-care division, posted 7.1% growth, but three dental segments declined. Tariff pressures and lower volumes squeezed operating margins, offsetting the strength in the healthcare unit. Free cash flow jumped to $55 million from $16 million in the year-ago quarter, a 244% improvement that provides near-term balance sheet flexibility.

The earnings beat came entirely from the bottom line—operational execution and cost discipline drove the surprise, not demand acceleration. Revenue contraction across core dental segments points to persistent end-market weakness, though the cash-flow surge offers a partial offset for value-oriented investors.